Top Markets
Coin of the day
Venus Medtech (Hangzhou) Inc. Venus Medtech (Hangzhou) Inc.

Venus Medtech (Hangzhou) Inc.

2500
株式のランク #24714
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the... Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
株価
$0.13048475
時価総額
$57.55M
変化(1日)
-1.92%
変化(1年)
-77.88%
CN
取引 Venus Medtech (Hangzhou) Inc. (2500)

カテゴリー

Venus Medtech (Hangzhou) Inc.(2500)の発行済株式数
August 2026 時点の発行済株式数 0
Venus Medtech (Hangzhou) Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Venus Medtech (Hangzhou) Inc.(2500)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数